Foreign Corrupt Practices Act (FCPA): How 2011 Enforcement Initiatives Will Affect Your Company

Since November of 2009, the Department of Justice (DOJ) has moved forward with its industry-wide pharmaceutical and medical device FCPA initiative.  The DOJ and the FBI's Washington Field Office (WFO) are taking aggressive action across the industries to enforce the FCPA's anti-bribery provisions.  With over twenty pharmaceutical and device companies being investigated for violating the FCPA's anti-bribery provisions, companies need to align global compliance programs and leverage their experience dealing with DOJ matters in developing integrated strategies for responding to FCPA inquiries.